Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

NCT06982352

Status	RECRUITING
Phase	Phase 1
Sponsor	LAPIX Therapeutics Inc.
Enrollment	48 participants

Key Eligibility Criteria

Inclusion (43)

- Subject has signed an Informed Consent Form (ICF) prior to any study-specific procedures being performed
- e 18 years old, irrespective of their race and ethnicity.
- Body Mass Index (BMI) 18.0-40.0 kg/m2, inclusive, at screening.
- Participants are willing and able to adhere to study protocol requirements and restrictions including but not limited to scheduled outpatient visits, inpatient stay, laboratory tests, and 12-lead ECGs.
- The subject must be judged to be in good health by the investigator to participate in the study, based on clinical evaluations, including laboratory safety tests, medical history, physical examination, vital signs and 12-lead ECG completed at the screening visit and prior to the first dose of study drug.

... and 38 more (see full listing online)

Exclusion (40)

- History of clinically significant medical conditions or any other reason that in the opinion of the PI would interfere with subject's participation in this study
- History of clinically significant drug or alcohol abuse per the PI's opinion within the last 6 months.
- Pregnant or lactating women or women currently undergoing infertility treatments or women who intend to become pregnant during the time of study or for 6 weeks after last dose.
- Presence of skin comorbidities that would interfere with study assessment or response to treatment
- Any known history of malignancy within 5 years other than completely treated non-metastatic basal cell carcinomas or squamous cell carcinomas of the skin or localized carcinoma in situ of the cervix.

... and 35 more (see full listing online)

Locations (3 total)

Red River Research Partners, Fargo, North Dakota, United States
Clinical Investigations of Texas, Dallas, Texas, United States
Triumpharma Clinical Research Unit at AlEssra Hospital, Amman, Jordan, Jordan